41/314US=23-E / Câncer
Spiess PE, Tannir NM, Pisters LL. Testicular cancer: post-chemotherapy retroperitoneal lymph node dissection. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 167-79. ISBN 978-90-481-2917-1.

CANCER DE TESTICULO; POS-QUIMIOTERAPIA; RETROPERITONEAL DISSECCAO DE LINFONODOS

42/314US=23-E / Câncer
Richiardi L, Maule MM. Survivors of germ-cell testicular cancer: increased risk of second primary tumors. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 181-91. ISBN 978-90-481-2917-1.

GERMES; CELULAS DE CANCER TESTICULAR; TUMOR PRIMARIO

43/314US=23-E / Câncer
Svatek RS, Lotan Y. Urothelial bladder cancer: screening with urine-based tumor markers. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 197-209. ISBN 978-90-481-2917-1.

CANCER DE BEXIGA UROTELIAL; TRIAGEM HEMATURIA; URINA BASEADO MARCADORES TUMORAIS

44/314US=23-E / Câncer
Mowla SJ, Jafarnejad SM, Atlasi Y. Detection of OCT-4 in bladder cancer: role of cancer stem cell. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 211-26. ISBN 978-90-481-2917-1.

DETECCAO DE OCT-4; CANCER DE BEXIGA; PAPEL DE CELULA-TRONCO DO CANCER

45/314US=23-E / Câncer
Baker AC, Grizzle WE, Chhieng D. Uterine cervical glandular lesions: differentiation using immunohistochemistry of mucins. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 231-42. ISBN 978-90-481-2917-1.

CERVICO-UTERINO; LESOES GLANDULARES; IMUNOHISTOQUIMICA DAS MUCINAS

46/314US=23-E / Câncer
Baker AC, Grizzle WE, Chhieng D. Uterine cervical glandular lesions: differentiation using immunohistochemistry of mucins. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 243-53. ISBN 978-90-481-2917-1.

CERVICO-UTERINO; LESOES GLANDULARES; IMUNOHISTOQUIMICA DE MUCINAS

47/314US=23-E / Câncer
Kato S, Ohno T. Cancer imaging and intracavitary brachytherapy for cervical cancer. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 257-62. ISBN 978-90-481-2917-1.

CANCER DE IMAGEM; BRAQUITERAPIA INTRACAVITARIA; CANCER CERVICAL

48/314US=23-E / Câncer
Greimel E. Cervical cancer: methods for assessing the quality of life. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 263-73. ISBN 978-90-481-2917-1.

CANCER DE COLO UTERINO; CANCER DE COLO UTERINO. QUALIDADE DE VIDA

49/314US=23-E / Câncer
Lin LL, Grigsby PW. Cervical cancer: positron emission tomography and positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 275-84. ISBN 978-90-481-2917-1.

CANCER CERVICAL; TOMOGRAFIA POR EMISSAO DE POSITRONS; TOMOGRAFIA POR EMISSAO DE POSITRONS/TOMOGRAFIA COMPUTADORIZADA

50/314US=23-E / Câncer
Ino K, Yamatomoto E, Shibata K, Kajiyama H, Nawa A, Kikkawa F. Cervical cancer: positron emission tomography and positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 275-84. ISBN 978-90-481-2917-1.

CANCER CERVICAL; TOMOGRAFIA POR EMISSAO DE POSITRONS; TOMOGRAFIA POR EMISSAO DE POSITRONS/TOMOGRAFIA COMPUTADORIZADA

51/314US=23-E / Câncer
Ino K, Yamatomoto E, Shibata K, Kajiyama H, Nawa A, Kikkawa F. Endometrial cancer: indoleamine 2,3-dioxygenase as a prognostic indicator. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 285-95. ISBN 978-90-481-2917-1.

CANCER DE ENDOMETRIO; 2,3-DIOXIGENASE INDOLEAMINA; INDICADOR DE PROGNOSTICO

52/314US=23-E / Câncer
Rübben A. Neurofibromatosis type 1-associated malignant melanoma: molecular evidence of inactivation of the NF1 gene. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 301-9. ISBN 978-90-481-2917-1.

NEUROFIBROMATOSE TIPO 1; MELANOMA MALIGNO; EVIDENCIA MOLECULAR DE INATIVACAO DO GENE NF1

53/314US=23-E / Câncer
Gheysens O, Mottaghy FM. Malignant melanoma: localisation and characterization using fluorodeoxyglucose-positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 311-22. ISBN 978-90-481-2917-1.

MELANOMA MALIGNO; FLUORODESOXIGLICOSE POR EMISSAO DE POSITRONS; TOMOGRAFIA COMPUTADORIZADA

54/314US=23-E / Câncer
Roesch A, Landthaler M, Vogt T. Malignant melanoma versus deep penetrating nevus:diagnostic and prognostic immunohistochemistry of dipeptidy1 peptidase IV (methodology). In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 323-31. ISBN 978-90-481-2917-1.

MELANOMA MALIGNO; IMUNO-HISTOQUIMICA; DIPEPTIDE; PEPTIDASE IV; DIPEPTIDIL PEPTIDASE-4; DPP4

55/314US=23-E / Câncer
Hafner C. Nonmelanoma skin cancer use of Epha1 receptor as a prognostic marker. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 333-40. ISBN 978-90-481-2917-1.

CANCER DE PELE; EPHA1 RECEPTOR

56/314US=23-E / Câncer
Fiegl M, Mayer J. Pretreated chronic lymphocytic leukemia: use of alemtuzumab. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 343-58. ISBN 978-90-481-2917-1.

LEUCEMIA CRONICA. TRATAMENTO; LINFOCITICA; TRATAMENTO COM USO DE ALEMTUZUMAB

57/314US=23-E / Câncer
Chatterjee M, Manivannan R, Pande A, Chakraborty T. Immunotherapeutic strategies, radiotherapy, and targeted radionuclide therapy approaches for the treatment of multiple myeloma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 361-82. ISBN 978-90-481-2917-1.

ESTRATEGIAS DE IMUNOTERAPIA; RADIOTERAPIA; TERAPIA; RADIONUCLIDEOS PARA O TRATAMENTO DO MIELOMA MULTIPLO

58/314US=23-E / Câncer
Matsuyama A, Hisaoka M, Hashimoto H. Low grade fibromyxoid sarcoma: diagnosis by detecting FUS-CREB3L2 fusion gene using reverse transcription-polymerase chain reaction. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 387-92. ISBN 978-90-481-2917-1.

SARCOMA DE BAIXO GRAU FIBROMIXOIDE; FUS-CREB3L2; GENE DE FUSAO. REACAO EM CADEIA DE POLIMERASE

59/314US=23-E / Câncer
Terry J, Nielsen TO. Synovial sarcoma: role of TLE1 as a diagnostic immunohistochemical marker. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 393-403. ISBN 978-90-481-2917-1.

SARCOMA SINOVIAL; TLE1 COMO MARCADOR; IMUNO-HISTOQUIMICA. DIAGNOSTICO

60/314US=23-E / Câncer
Pantanowitz L, Caponetti G, Dezube BJ. The immunohistochemistry of Kaposi's sarcoma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 405-31. ISBN 978-90-481-2917-1.

IMUNO-HISTOQUIMICA DE SARCOMA DE KAPOSI; SARCOMA DE KAPOSI

Primeira | Anterior | Próxima | Última